tldrdailynews.com logo

"Vertex Pharmaceuticals' $4.9B Acquisition of Alpine Expands Focus to Kidney and Autoimmune Diseases"

1 min read
Source: Endpoints News
"Vertex Pharmaceuticals' $4.9B Acquisition of Alpine Expands Focus to Kidney and Autoimmune Diseases"
Photo: Endpoints News
TL;DR

Vertex Pharmaceuticals has announced a $4.9 billion deal to acquire Alpine Immune Sciences and its experimental drug povetacicept, aimed at treating IgA nephropathy, a kidney disease. The acquisition will expand Vertex's work in kidney and autoimmune diseases, marking a significant investment from the biotech company.

Topics:businessbusiness-healthcare#acquisition#alpine-immune-sciences#autoimmune-disease#business-healthcare#kidney-disease#vertex
Share this article
  1. Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease  Endpoints News
  2. Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion  CNBC
  3. Vertex to Buy Kidney Disease Drug Developer for $4.9 Billion  Bloomberg
  4. Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition  MarketWatch
  5. Why Janux Therapeutics Stock Soared as the Market Sagged Today  The Motley Fool

Want the full story? Read the original reporting

Read on Endpoints News